Literature DB >> 24855946

Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.

John T Cunningham1, Melissa V Moreno1, Alessia Lodi2, Sabrina M Ronen2, Davide Ruggero3.   

Abstract

Cancer cells must integrate multiple biosynthetic demands to drive indefinite proliferation. How these key cellular processes, such as metabolism and protein synthesis, crosstalk to fuel cancer cell growth is unknown. Here, we uncover the mechanism by which the Myc oncogene coordinates the production of the two most abundant classes of cellular macromolecules, proteins, and nucleic acids in cancer cells. We find that a single rate-limiting enzyme, phosphoribosyl-pyrophosphate synthetase 2 (PRPS2), promotes increased nucleotide biosynthesis in Myc-transformed cells. Remarkably, Prps2 couples protein and nucleotide biosynthesis through a specialized cis-regulatory element within the Prps2 5' UTR, which is controlled by the oncogene and translation initiation factor eIF4E downstream Myc activation. We demonstrate with a Prps2 knockout mouse that the nexus between protein and nucleotide biosynthesis controlled by PRPS2 is crucial for Myc-driven tumorigenesis. Together, these studies identify a translationally anchored anabolic circuit critical for cancer cell survival and an unexpected vulnerability for "undruggable" oncogenes, such as Myc. PAPERFLICK:
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24855946      PMCID: PMC4140650          DOI: 10.1016/j.cell.2014.03.052

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  46 in total

1.  Regulation of ribosomal protein mRNA content and translation in growth-stimulated mouse fibroblasts.

Authors:  P K Geyer; O Meyuhas; R P Perry; L F Johnson
Journal:  Mol Cell Biol       Date:  1982-06       Impact factor: 4.272

2.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics.

Authors:  Frank Dieterle; Alfred Ross; Götz Schlotterbeck; Hans Senn
Journal:  Anal Chem       Date:  2006-07-01       Impact factor: 6.986

Review 3.  Regulation of cancer cell metabolism.

Authors:  Rob A Cairns; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

4.  Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.

Authors:  Andrew C Hsieh; Davide Ruggero
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

5.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

6.  Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Authors:  Joanne R Doherty; Chunying Yang; Kristen E N Scott; Michael D Cameron; Mohammad Fallahi; Weimin Li; Mark A Hall; Antonio L Amelio; Jitendra K Mishra; Fangzheng Li; Mariola Tortosa; Heide Marika Genau; Robert J Rounbehler; Yunqi Lu; Chi V Dang; K Ganesh Kumar; Andrew A Butler; Thomas D Bannister; Andrea T Hooper; Keziban Unsal-Kacmaz; William R Roush; John L Cleveland
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

7.  Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells.

Authors:  M Eilers; D Picard; K R Yamamoto; J M Bishop
Journal:  Nature       Date:  1989-07-06       Impact factor: 49.962

8.  The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry.

Authors:  Fionnuala Morrish; Nicola Neretti; John M Sedivy; David M Hockenbery
Journal:  Cell Cycle       Date:  2008-02-08       Impact factor: 4.534

9.  Cloning of cDNAs for human phosphoribosylpyrophosphate synthetases 1 and 2 and X chromosome localization of PRPS1 and PRPS2 genes.

Authors:  M A Becker; S A Heidler; G I Bell; S Seino; M M Le Beau; C A Westbrook; W Neuman; L J Shapiro; T K Mohandas; B J Roessler
Journal:  Genomics       Date:  1990-11       Impact factor: 5.736

10.  The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells.

Authors:  A W Harris; C A Pinkert; M Crawford; W Y Langdon; R L Brinster; J M Adams
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  100 in total

Review 1.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

Review 2.  The Untranslated Regions of mRNAs in Cancer.

Authors:  Samantha L Schuster; Andrew C Hsieh
Journal:  Trends Cancer       Date:  2019-03-22

Review 3.  MYC and metabolism on the path to cancer.

Authors:  Annie L Hsieh; Zandra E Walton; Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Semin Cell Dev Biol       Date:  2015-08-12       Impact factor: 7.727

Review 4.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 5.  Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine.

Authors:  Ji Zhang; Natalya N Pavlova; Craig B Thompson
Journal:  EMBO J       Date:  2017-04-18       Impact factor: 11.598

Review 6.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells.

Authors:  Russell G Jones; Edward J Pearce
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

Review 7.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

8.  Development of a stress response therapy targeting aggressive prostate cancer.

Authors:  Hao G Nguyen; Crystal S Conn; Yae Kye; Lingru Xue; Craig M Forester; Janet E Cowan; Andrew C Hsieh; John T Cunningham; Charles Truillet; Feven Tameire; Michael J Evans; Christopher P Evans; Joy C Yang; Byron Hann; Constantinos Koumenis; Peter Walter; Peter R Carroll; Davide Ruggero
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

9.  Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation.

Authors:  Sophia Y Lunt; Vinayak Muralidhar; Aaron M Hosios; William J Israelsen; Dan Y Gui; Lauren Newhouse; Martin Ogrodzinski; Vivian Hecht; Kali Xu; Paula N Marín Acevedo; Daniel P Hollern; Gary Bellinger; Talya L Dayton; Stefan Christen; Ilaria Elia; Anh T Dinh; Gregory Stephanopoulos; Scott R Manalis; Michael B Yaffe; Eran R Andrechek; Sarah-Maria Fendt; Matthew G Vander Heiden
Journal:  Mol Cell       Date:  2014-12-04       Impact factor: 17.970

10.  Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.

Authors:  Liangxian Cao; Marla Weetall; Christopher Trotta; Katherine Cintron; Jiyuan Ma; Min Jung Kim; Bansri Furia; Charles Romfo; Jason D Graci; Wencheng Li; Joshua Du; Josephine Sheedy; Jean Hedrick; Nicole Risher; Shirley Yeh; Hongyan Qi; Tamil Arasu; Seongwoo Hwang; William Lennox; Ronald Kong; Janet Petruska; Young-Choon Moon; John Babiak; Thomas W Davis; Allan Jacobson; Neil G Almstead; Art Branstrom; Joseph M Colacino; Stuart W Peltz
Journal:  Mol Cancer Ther       Date:  2018-10-23       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.